FGF2-Binding Peptides Inhibit Angiogenesis Without Immune Impact
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective, non-immunogenic methods to inhibit the pro-angiogenic activity of Fibroblast Growth Factor-2 (FGF2) without impacting innate immunity, as large molecules like PTX3 have unfeasible therapeutic applications due to their size and other activities.
Innovation Solution
Development of short FGF2-binding peptides, such as PTX3(82-110), PTX3(97-110), PTX3(97-107), and PTX3(100-104, which bind FGF2 and inhibit its interaction with endothelial cells, preventing angiogenesis without affecting innate immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long PTX3 is used to bind FGF2 and inhibit its pro-angiogenic activity, then FGF2-dependent endothelial cell proliferation and angiogenesis are inhibited, but the large size and multiple activities of PTX3 make it unsuitable for therapeutic applications
Solution Approach 1:
The patent divides the long PTX3 molecule into smaller functional segments, specifically identifying and utilizing the N-terminal region (residues 1-178) and further refining to the critical FGF2-binding domain (residues 82-110). This segmentation allows the therapeutic agent to retain FGF2 inhibition efficacy while reducing the complexity and size issues of the full-length PTX3 molecule.
Solution Approach 2:
The patent extracts the essential FGF2-binding function from the complex PTX3 molecule by identifying and isolating the specific N-terminal region (residues 82-110) that contains the FGF2-binding epitope. This extracted peptide fragment maintains the desired therapeutic effect of inhibiting FGF2-mediated angiogenesis without the unwanted side effects and complexity of the full PTX3 molecule.
2Device complexity
If short peptides are designed to bind FGF2, then therapeutic applicability is improved, but the ability to effectively inhibit FGF2 interaction with endothelial cells must be maintained
Solution Approach 1:
The patent applies local quality by focusing on the specific region of PTX3 that possesses the critical FGF2-binding property. By identifying residues 82-110 as the essential binding domain and designing peptides centered around this region (with core sequence ESXARPCAPGAPAE where X is Arg or Lys), the invention concentrates the binding functionality in a localized short peptide sequence, achieving both reduced size and maintained affinity.
3Object-affected harmful factors
If FGF2 pro-angiogenic activity is inhibited, then conditions like tumor metastasis and diabetic retinopathy are treated, but innate immunity function must not be affected
Solution Approach 1:
The patent converts the potential harm of affecting immune function into a benefit by specifically designing peptides that target only the FGF2-binding site on PTX3. By focusing on the N-terminal region (residues 82-110) that is responsible for FGF2 binding but not for immune recognition functions, the invention achieves selective inhibition of pro-angiogenic activity while preserving innate immunity, effectively converting the challenge of specificity into a therapeutic advantage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides effectively inhibit FGF2-induced proliferation and angiogenesis in vitro and in vivo, offering a therapeutic potential for conditions like arthritic diseases, tumor metastasis, and diabetic retinopathy without immunogenic responses.
Implementation Method 1
synthetic peptides PTX3(82-110), PTX3(97-110), PTX3(97-107) and PTX3 (100-104) bind FGF2 and inhibit the interaction of FGF2 with whole long PTX3
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3B
AI summary
FGF2-binding peptides are here described, which have been designed starting from the N-terminal region of PTX3, in particular spanning the PTX3(82-110) region. Synthetic peptides related to this sequence are able to bind FGF2 and to inhibit its pro-angiogenic activity in vitro and in vivo with no anticipated impact on innate immunity.